medigraphic.com

2012, Number 3

<< Back Next >>

Rev Cuba Endoc 2012; 23 (3)

Thyroid orbitopathy

Maciques RJE, Cáceres TM

Language: Spanish
References: 28
Page:
PDF size: 195.86 Kb.


ABSTRACT

Thyroid orbitopathy, also known as Graves' orbitopathy, is an inflammatory, autoimmune, and self-limiting disease that affects orbital and periorbital tissues. It is more frequent in women and linked to hyperthyroidism condition, although it may occur in hypothyroid and euthyroid patients, worsened by smoking and stress. It is mainly characterized by palpebral retraction and exophtalmos, but it may sometimes evolve into severe forms with significant impact on the vision due to compressive optic neuropathy or the loss of the eyeball integrity. The treatment ranges from simple protection of the eyeball in the milder forms, the use of glycocorticoids or other immunosuppressive drugs to the orbital decompression surgery in the most severe cases, which are increasingly less painful and more hopeful. This review was aimed at standardizing and updating the knowledge on this disease and at providing practical information for the early diagnosis and the adequate treatment of our patients.


REFERENCES

  1. Brent GA. Graves' Disease. N Eng J Med. 2008;358:2594-605.

  2. Eckstein A, Losch C, Glowacka D. Euthyroid and primary hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 2009;93:1052-6.

  3. Ocna N, Bystrica P. Epidemiology of the endocrine orbitopathy. Cesk Slov Oftalmol. 2006;62(6):373-80.

  4. Navarro Despaigne D. Epidemiología de las enfermedades del tiroides en Cuba. Rev Cubana Endocrinol [serie en Internet]. 2004 Abr [citado 3 de noviembre de 2012];15(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532004000100004&lng=es&nrm=iso&tlng=es

  5. Bradley EA. Graves ophthalmopathy. Curr Opin Opthalmol. 2001;12:347-51.

  6. Pérez Moreiras JV, Prada Sánchez MC. Oftalmopatía Distiroidea. Barcelona: Edika Med; 1997. p. 91-7.

  7. Asman P. Ophthalmological evaluation in thyroid-associated ophthalmopathy. Acta Ophthalmol Scand. 2003 Oct;81(5):437-48.

  8. Kanski JC. Oftalmología Clínica. 5ª ed. España: Elsevier; 2004. p. 82-4.

  9. Gerding MN, Prummel MF, Wiersinga WM. Assessment of disease activity in Graves' opthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol. 2000; 52:641-6.

  10. Kvetny J, Puhakka KB, Rohl L. Magnetic resonance imaging determination of extraocular eye muscle volume in patients with thyroid-associated ophthalmopathy and proptosis. Acta Ophthalmol Scand. 2006;84(3):419-23.

  11. Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977;44:203-4.

  12. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, Van der Gaag R. Clinical criteria for the assessment of disease activity in Graves'ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639-40.

  13. Bahn R. The EUGOGO Consensus statement on the management of Graves' orbitopathy on management: equally applicable to North American clinicians and patients. Thyroid. 2008;18:281-2.

  14. Bartelena L, Marcocci C, Tanda ML, Pinchera A. Management of thyroid eye disease. Eur J Nucl Med. 2002;29:458-65.

  15. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349-52.

  16. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs. lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996;45:477-81.

  17. Vestergaard P. Smoking and thyroid disorders. A meta-analysis. Eur J Endocrinol. 2002;146:153-61.

  18. Prummel MF, Wiersinga WM, Mourits MP. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med. 1990;150:1098.

  19. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-8.

  20. Robertson DM, Buettner H, Gorman CA. Retinal microvascular abnormalities in patients treated with external radiation for Graves' ophthalmopathy. Arch Ophthalmol. 2003 May;121(5):652-7.

  21. Cockerham KC, Kennerdell JS. Does radiotherapy have a role in the management of thyroid orbitopathy? View 1. Br J Ophthalmol. 2002;86:102-7.

  22. Van Geest RJ, Sasim IV, Koppeschaar HP, Kalmann R, Stravers SN, Bijlsma WR, Mourits MP. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158(2):229-37.

  23. Cáceres M, Márquez M, Caballero Y, Córdova G. Descompresión orbitaria en la orbitopatía tiroidea. Rev Cubana Oftalmol [serie en Internet]. 2008 Jun [citado 3 de noviembre de 2012];21(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762008000100001&lng=es

  24. Espinosa A, Galán A, Medel R, Alonso T. Estrabismos tras descompresión orbitaria. Características y manejo. Acta Estrabológica. 2007;36:1-5.

  25. Dintelmann T, Sold J, Grehn F. Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease. Ophthalmologe. 2005;102:247-50.

  26. Mauricio J, Lozano V. Uso de la toxina botulínica en el estrabismo. Revista Franja Ocular. 2003;4(24):16-8.

  27. Pérez Moreiras JV, Coloma Bockos JE, Prada Sánchez MC. Orbitopatía tiroidea (fisiopatología, diagnóstico y tratamiento). Arch Soc Esp Oftalmol. 2003;78:407-31.

  28. Coulter I, Krassas GE, Frewin I, Perros SP. Psychological implications of Graves' orbitopathy. European Journal of Endocrinology. 2007;157:127-31.




2020     |     www.medigraphic.com